CHMP January 2026 Approvals: Expanding Access t...

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The
Characterizing Burnout in Health Professionals: Insights from the BEATS Study...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Driving Economic Transformation through Brain Health Investment in Africa